peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

calcium-regulating hormone

Calcitonin

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

The product’s active peptide is specified as a 32–amino-acid synthetic polypeptide that matches the linear amino-acid sequence of salmon calcitonin. Calcitonin functions as a full agonist at the human AMY2 receptor, with potency/affinity reported as pEC50 11.4. They measured PMA, light aversion, and facial grimace as migraine-relevant behaviors. A labeled contraindication is clinical allergy to the calcitonin-salmon peptide.

Sources for this introduction: [1] [2] [3] [4]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

The label identifies the drug product as synthetic calcitonin salmon injection meeting USP designation.

Sources[2]dailymedCALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useCalcitonin Salmon Injection, USP, Synthetic
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Calcitonin Salmon Injection, USP, Synthetic”

    CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular use · PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    dailymed:6a0fdcc3-9dca-4936-8601-9ec87457263d:831a858c8634:831a858c8634

Identity

The product’s active peptide is specified as a 32–amino-acid synthetic polypeptide that matches the linear amino-acid sequence of salmon calcitonin.

Sources[1]dailymedCalcitonin-SalmonNasal Spray, USPRx OnlyPrescribing InformationCalcitonin-Salmon Nasal Spray is a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Calcitonin-Salmon Nasal Spray is a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin.”

    Calcitonin-SalmonNasal Spray, USPRx OnlyPrescribing Information · DESCRIPTION

    dailymed:1d20ac74-4cd8-4277-9e43-79df44c26254:6b02935f249d:6b02935f249d

Identity

This formulation’s active peptide is recombinant calcitonin-salmon consisting of 32 amino acids, stated to be identical to the chemically synthesized peptide.

Sources[5]dailymedFORTICAL®calcitonin-salmon(rDNA origin)Nasal SprayThe active ingredient in FORTICAL®calcitonin-salmon (rDNA origin) Nasal Spray is a polypeptide of 32 amino acids manufactured by recombinant DNA technology and is identical to calcitonin-salmon produced by chemical synthesis.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The active ingredient in FORTICAL®calcitonin-salmon (rDNA origin) Nasal Spray is a polypeptide of 32 amino acids manufactured by recombinant DNA technology and is identical to calcitonin-salmon produced by chemical synthesis.”

    FORTICAL®calcitonin-salmon(rDNA origin)Nasal Spray · DESCRIPTION

    dailymed:e662c321-8c1b-4829-b4c9-459284f654c3:302ea99274f7:302ea99274f7

How does it work?

Target, response, and disposition.

Mechanism

Calcitonin functions as a full agonist at the human AMY2 receptor, with potency/affinity reported as pEC50 11.4.

Sources[6]iuphar-interactionsIUPHAR interactions for calcitoninLigand: calcitonin Target: AMY<sub>2</sub> receptor (Human) Action: Full agonist Primary target: no Affinity: pEC50 11.4 References: PMID 11033437
Reported result
pEC50 11.4
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Ligand: calcitonin Target: AMY<sub>2</sub> receptor (Human) Action: Full agonist Primary target: no Affinity: pEC50 11.4 References: PMID 11033437”

    IUPHAR interactions for calcitonin · Interaction 2123

    iuphar-interactions:685:3f42ccfa44b2:3f42ccfa44b2

Pharmacokinetics

This section reports a short terminal half-life (around 18 minutes) for calcitonin-salmon and indicates no observable accumulation after repeated dosing.

Sources[5]dailymedFORTICAL®calcitonin-salmon(rDNA origin)Nasal SprayThe terminal half-life of calcitonin-salmon has been calculated to be around 18 minutes and no evidence of accumulation was observed with multiple dosing.
Reported result
Terminal half-life around 18 minutes
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The terminal half-life of calcitonin-salmon has been calculated to be around 18 minutes and no evidence of accumulation was observed with multiple dosing.”

    FORTICAL®calcitonin-salmon(rDNA origin)Nasal Spray · Pharmacokinetics and Drug Metabolism

    dailymed:e662c321-8c1b-4829-b4c9-459284f654c3:302ea99274f7:302ea99274f7

Pharmacokinetics

Intranasal calcitonin-salmon shows low systemic bioavailability (3–5% vs IM) with rapid absorption through nasal mucosa (mean Tmax about 13 minutes).

Sources[5]dailymedFORTICAL®calcitonin-salmon(rDNA origin)Nasal SprayThe bioavailability of calcitonin-salmon nasal spray relative to intramuscular administration is between 3 and 5%. Calcitonin-salmon nasal spray is absorbed by the nasal mucosa with a mean Tmax of about 13 minutes.
Reported result
Bioavailability between 3 and 5% (relative to intramuscular); mean Tmax about 13 minutes
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The bioavailability of calcitonin-salmon nasal spray relative to intramuscular administration is between 3 and 5%. Calcitonin-salmon nasal spray is absorbed by the nasal mucosa with a mean Tmax of about 13 minutes.”

    FORTICAL®calcitonin-salmon(rDNA origin)Nasal Spray · Pharmacokinetics and Drug Metabolism

    dailymed:e662c321-8c1b-4829-b4c9-459284f654c3:302ea99274f7:302ea99274f7

What has been studied?

What the evidence says.

Study findings

They measured PMA, light aversion, and facial grimace as migraine-relevant behaviors.

Sources[7]pubmedSystematic comparison of GTN- and CGRP-induced migraine-like behaviors across sex and strain in mice.assessed using three commonly employed migraine-relevant readouts: periorbital mechanical allodynia (PMA), light aversion, and facial grimace scoring.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “assessed using three commonly employed migraine-relevant readouts: periorbital mechanical allodynia (PMA), light aversion, and facial grimace scoring.”

    Systematic comparison of GTN- and CGRP-induced migraine-like behaviors across sex and strain in mice. · Abstract

    pubmed:42331065:a8103cef48f7:a8103cef48f7

Risks and interactions

Risks, organized for scanning.

Contraindications

A labeled contraindication is hypersensitivity to the active peptide (calcitonin salmon) or to formulation excipients.

Sources[4]dailymedThese highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975Hypersensitivity to calcitonin salmon or any of the excipients.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Hypersensitivity to calcitonin salmon or any of the excipients.”

    These highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975 · 4 CONTRAINDICATIONS

    dailymed:c82eb602-12e1-692b-d660-f8d5b5736b54:0937cbe47027:0937cbe47027

Contraindications

The contraindication listed is hypersensitivity/clinical allergy specifically to calcitonin-salmon.

Sources[1]dailymedCalcitonin-SalmonNasal Spray, USPRx OnlyPrescribing InformationClinical allergy to calcitonin-salmon
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Clinical allergy to calcitonin-salmon”

    Calcitonin-SalmonNasal Spray, USPRx OnlyPrescribing Information · CONTRAINDICATIONS

    dailymed:1d20ac74-4cd8-4277-9e43-79df44c26254:6b02935f249d:6b02935f249d

Contraindications

The label lists hypersensitivity to calcitonin salmon or formulation excipients as a contraindication for calcitonin salmon injection.

Sources[3]dailymedThese highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975Hypersensitivity to calcitonin salmon or any of the excipients.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Hypersensitivity to calcitonin salmon or any of the excipients.”

    These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 · 4 CONTRAINDICATIONS

    dailymed:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc:4c5ecbacdf1a:4c5ecbacdf1a

Contraindications

A labeled contraindication is clinical allergy to the calcitonin-salmon peptide.

Sources[5]dailymedFORTICAL®calcitonin-salmon(rDNA origin)Nasal SprayClinical allergy to calcitonin-salmon.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Clinical allergy to calcitonin-salmon.”

    FORTICAL®calcitonin-salmon(rDNA origin)Nasal Spray · CONTRAINDICATIONS

    dailymed:e662c321-8c1b-4829-b4c9-459284f654c3:302ea99274f7:302ea99274f7

Products and regulatory status

Same ingredient. Different records.

Regulatory status

Calcitonin salmon injection has a labeled indication for postmenopausal osteoporosis restricted to women greater than 5 years postmenopause.

Sources[3]dailymedThese highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975Calcitonin salmon injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Calcitonin salmon injection is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause.”

    These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 · 1.3 Treatment of Postmenopausal Osteoporosis

    dailymed:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc:4c5ecbacdf1a:4c5ecbacdf1a

Regulatory status

Calcitonin salmon injection has a labeled indication for early management of hypercalcemic emergencies as an adjunct when rapid lowering of serum calcium is required while definitive treatment is pursued.

Sources[3]dailymedThese highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975Calcitonin salmon injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Calcitonin salmon injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished.”

    These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 · 1.2 Treatment of Hypercalcemia

    dailymed:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc:4c5ecbacdf1a:4c5ecbacdf1a

Regulatory status

The approved indication for intranasal calcitonin salmon includes treatment of osteoporosis in women who are more than 5 years postmenopause.

Sources[4]dailymedThese highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975Calcitonin Salmon (synthetic origin) Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Calcitonin Salmon (synthetic origin) Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause.”

    These highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975 · 1.1 Treatment of Postmenopausal Osteoporosis

    dailymed:c82eb602-12e1-692b-d660-f8d5b5736b54:0937cbe47027:0937cbe47027

Regulatory status

Calcitonin salmon injection has a labeled indication for symptomatic Paget’s disease of bone in moderate to severe cases defined by polyostotic involvement plus elevated biochemical markers (serum alkaline phosphatase and urinary hydroxyproline excretion).

Sources[3]dailymedThese highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975Calcitonin salmon injection is indicated for the treatment of symptomatic Paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Calcitonin salmon injection is indicated for the treatment of symptomatic Paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion.”

    These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 · 1.1 Treatment of Paget’s Disease of Bone

    dailymed:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc:4c5ecbacdf1a:4c5ecbacdf1a

Regulatory status

Labeling recommends reserving calcitonin salmon nasal spray for patients who cannot use alternative therapies (e.g., contraindicated, intolerant, or unwilling).

Sources[4]dailymedThese highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975Calcitonin Salmon (synthetic origin) Nasal Spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies).
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Calcitonin Salmon (synthetic origin) Nasal Spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies).”

    These highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975 · 1.1 Treatment of Postmenopausal Osteoporosis

    dailymed:c82eb602-12e1-692b-d660-f8d5b5736b54:0937cbe47027:0937cbe47027

Administration context

The practical clinical context.

Administration

Concomitant supplementation is recommended: ≥1000 mg/day elemental calcium and ≥400 IU/day vitamin D during calcitonin salmon nasal spray use.

Sources[4]dailymedThese highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975Patients who use calcitonin salmon nasal spray should receive adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day).
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Patients who use calcitonin salmon nasal spray should receive adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day).”

    These highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975 · 2.3 Recommendations for Calcium and Vitamin D Supplementation

    dailymed:c82eb602-12e1-692b-d660-f8d5b5736b54:0937cbe47027:0937cbe47027

Administration

The container presentation is a multiple-dose vial with a labeled volume of 2 mL.

Sources[2]dailymedCALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular use2 mL Multiple-Dose vial
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “2 mL Multiple-Dose vial”

    CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular use · PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    dailymed:6a0fdcc3-9dca-4936-8601-9ec87457263d:831a858c8634:831a858c8634

Administration

The labeled routes of administration are intramuscular (IM) or subcutaneous (SC).

Sources[2]dailymedCALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useFor Intramuscular or Subcutaneous Use
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “For Intramuscular or Subcutaneous Use”

    CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular use · PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    dailymed:6a0fdcc3-9dca-4936-8601-9ec87457263d:831a858c8634:831a858c8634

Administration

Metered-dose delivery per actuation from a primed pump is 0.09 mL corresponding to 200 USP Calcitonin Salmon Units of calcitonin salmon.

Sources[4]dailymedThese highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975A primed pump delivers 0.09 mL (200 USP Calcitonin Salmon Units) calcitonin salmon per actuation.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “A primed pump delivers 0.09 mL (200 USP Calcitonin Salmon Units) calcitonin salmon per actuation.”

    These highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975 · 3 DOSAGE FORMS AND STRENGTHS

    dailymed:c82eb602-12e1-692b-d660-f8d5b5736b54:0937cbe47027:0937cbe47027

Dose records

Recommended dosing for postmenopausal osteoporosis (women >5 years postmenopause) is calcitonin salmon injection 100 USP Units (0.5 mL) once daily via subcutaneous or intramuscular route.

Sources[3]dailymedThese highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975The recommended dose of calcitonin salmon injection for treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause is 100 USP Units (0.5 mL) per day administered subcutaneously or intramuscularly.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dose of calcitonin salmon injection for treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause is 100 USP Units (0.5 mL) per day administered subcutaneously or intramuscularly.”

    These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 · 2.3 Postmenopausal Osteoporosis

    dailymed:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc:4c5ecbacdf1a:4c5ecbacdf1a

Dose records

For postmenopausal osteoporotic patients, the labeled regimen is 200 International Units once daily by intranasal spray with daily alternation of nostril.

Sources[5]dailymedFORTICAL®calcitonin-salmon(rDNA origin)Nasal SprayThe recommended dose of FORTICAL®calcitonin-salmon (rDNA origin) Nasal Spray in postmenopausal osteoporotic patients is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dose of FORTICAL®calcitonin-salmon (rDNA origin) Nasal Spray in postmenopausal osteoporotic patients is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily.”

    FORTICAL®calcitonin-salmon(rDNA origin)Nasal Spray · DOSAGE AND ADMINISTRATION

    dailymed:e662c321-8c1b-4829-b4c9-459284f654c3:302ea99274f7:302ea99274f7

Dose records

The labeled concentration is 2200 I.U. per mL, and each metered actuation delivers 0.09 mL for a 200 I.U. dose.

Sources[1]dailymedCalcitonin-SalmonNasal Spray, USPRx OnlyPrescribing InformationActive Ingredient:calcitonin-salmon, 2200 I.U. per mL (corresponding to 200 I.U. per 0.09 mL actuation).
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Active Ingredient:calcitonin-salmon, 2200 I.U. per mL (corresponding to 200 I.U. per 0.09 mL actuation).”

    Calcitonin-SalmonNasal Spray, USPRx OnlyPrescribing Information · DESCRIPTION

    dailymed:1d20ac74-4cd8-4277-9e43-79df44c26254:6b02935f249d:6b02935f249d

Dose records

Calcitonin salmon nasal spray dosing is 200 USP units intranasally once daily with alternating nostrils to reduce local nasal exposure.

Sources[4]dailymedThese highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975The recommended dose of calcitonin salmon nasal spray is 1 spray (200 USP Calcitonin Salmon Units) per day administered intranasally, alternating nostrils daily.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dose of calcitonin salmon nasal spray is 1 spray (200 USP Calcitonin Salmon Units) per day administered intranasally, alternating nostrils daily.”

    These highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975 · 2.1 Basic Dosing Information

    dailymed:c82eb602-12e1-692b-d660-f8d5b5736b54:0937cbe47027:0937cbe47027

Dose records

Recommended dosing for symptomatic Paget’s disease of bone is calcitonin salmon injection 100 USP Units (0.5 mL) once daily via subcutaneous or intramuscular route.

Sources[3]dailymedThese highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975The recommended dose of calcitonin salmon injection for treatment of symptomatic Paget’s disease of bone is 100 USP Units (0.5 mL) per day administered subcutaneously or intramuscularly.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dose of calcitonin salmon injection for treatment of symptomatic Paget’s disease of bone is 100 USP Units (0.5 mL) per day administered subcutaneously or intramuscularly.”

    These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 · 2.1 Paget’s Disease of Bone

    dailymed:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc:4c5ecbacdf1a:4c5ecbacdf1a

Dose records

The metered intranasal actuation is specified as 200 International Units delivered per 0.09 mL spray.

Sources[5]dailymedFORTICAL®calcitonin-salmon(rDNA origin)Nasal SprayEach spray delivers 200 International Units calcitonin-salmon in a volume of 0.09 mL.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Each spray delivers 200 International Units calcitonin-salmon in a volume of 0.09 mL.”

    FORTICAL®calcitonin-salmon(rDNA origin)Nasal Spray · DESCRIPTION

    dailymed:e662c321-8c1b-4829-b4c9-459284f654c3:302ea99274f7:302ea99274f7

Dose records

The label recommends initiating calcitonin salmon injection for early hypercalcemia treatment at 4 USP Units/kg on a q12h schedule via subcutaneous or intramuscular route.

Sources[3]dailymedThese highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975The recommended starting dose of calcitonin salmon injection for early treatment of hypercalcemia is 4 USP Units/kg body weight every 12 hours by subcutaneous or intramuscular injection.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended starting dose of calcitonin salmon injection for early treatment of hypercalcemia is 4 USP Units/kg body weight every 12 hours by subcutaneous or intramuscular injection.”

    These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 · 2.2 Hypercalcemia

    dailymed:7d4507aa-8e10-44a6-bc6e-3176aa8b23cc:4c5ecbacdf1a:4c5ecbacdf1a

Dose records

The labeled regimen for postmenopausal osteoporosis is intranasal calcitonin-salmon 200 I.U. once daily, with alternating nostrils to distribute local exposure.

Sources[1]dailymedCalcitonin-SalmonNasal Spray, USPRx OnlyPrescribing InformationThe recommended dose of Calcitonin-Salmon Nasal Spray in postmenopausal osteoporotic females is one spray (200 I.U.) per day administered intranasally, alternating nostrils daily.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dose of Calcitonin-Salmon Nasal Spray in postmenopausal osteoporotic females is one spray (200 I.U.) per day administered intranasally, alternating nostrils daily.”

    Calcitonin-SalmonNasal Spray, USPRx OnlyPrescribing Information · DOSAGE AND ADMINISTRATION

    dailymed:1d20ac74-4cd8-4277-9e43-79df44c26254:6b02935f249d:6b02935f249d

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: interaction, safety
  • 97 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (62), assurance_score_below_0.72 (29), current_regulatory_source_required (18), extraction_ambiguity (77), extraction_confidence_not_high (1), high_risk_requires_regulatory_or_two_independent_sources (33), no_direct_support (90), proposal_not_staged (1)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Calcitonin-SalmonNasal Spray, USPRx OnlyPrescribing Information ↗

    dailymed · published 2011-12-12 · retrieved 2026-09-04T19:13:06Z

  2. CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular use ↗

    dailymed · published 2026-03-06 · retrieved 2026-09-04T19:12:55Z

  3. These highlights do not include all the information needed to use CALCITONIN SALMON injection safely and effectively. See full prescribing information for CALCITONIN SALMON injection.CALCITONIN SALMON injection, synthetic, for subcutaneous or intramuscular useInitial U.S. Approval: 1975 ↗

    dailymed · published 2024-07-10 · retrieved 2026-09-04T19:12:56Z

  4. These highlights do not include all the information needed to useCALCITONIN SALMON NASAL SPRAYsafely and effectively. See full prescribing information forCALCITONIN SALMON NASAL SPRAY.CALCITONIN SALMONnasal sprayInitial U.S. Approval: 1975 ↗

    dailymed · published 2025-09-17 · retrieved 2026-09-04T19:13:01Z

  5. FORTICAL®calcitonin-salmon(rDNA origin)Nasal Spray ↗

    dailymed · published 2010-01-15 · retrieved 2026-09-04T19:12:54Z

  6. IUPHAR interactions for calcitonin ↗

    iuphar-interactions · published 2026-08-25 · retrieved 2026-08-25T22:58:23Z

  7. Systematic comparison of GTN- and CGRP-induced migraine-like behaviors across sex and strain in mice. ↗

    pubmed · published 2026-09-13 · retrieved 2026-08-25T22:58:23Z

Publication history and provenance

Version 7 · Automated assessment · 2026-09-04T19:13:06Z

0f4c44afe106ec955d01d8dd92eae7af3338efcf415bf744f6a3f9fe166002a1